Publications:166
Video Visit Available
Accepting New Patients
Mount Sinai DoctorsTreats Adults
Accepting New PatientsDavid Perlman, MD
Infectious Disease
Book an Appointment
About Me
David C. Perlman, MD is Professor of Medicine and Associate Chief, Infectious Diseases at Mount Sinai Beth Israel. He is also Investigator in the Baron Edmund De Rothschild Chemical Dependency Institute at Mount Sinai Beth Israel, and a member of the Institute of Advanced Medicine.
He has over 20 years’ experience in HIV, HCV and related in substance using population and remains active as a clinician in these areas. He has served as principal investigator on multi-center trials within NIAID’s AIDS Clinical Trials group, and on R01 grants from NIDA. He has served on NIH study sections, CDC consensus panels, committees within the ACTG and the NYS DOH AIDS Institute, and the Planning Committee of the NYCDOMH New York Hepatitis C Research Consortium. He is the Director, Infectious Diseases Core, in the NIDA-funded multi-institutional P30 Center for Drug Use and HIV Research (CDUHR) where his role is to facilitate multi-disciplinary interactions and research among biomedical and socio-behavioral scientists.
He is an active clinician, doing inpatient consultative infectious diseases and a full range of office infectious diseases.
He has over 20 years’ experience in HIV, HCV and related in substance using population and remains active as a clinician in these areas. He has served as principal investigator on multi-center trials within NIAID’s AIDS Clinical Trials group, and on R01 grants from NIDA. He has served on NIH study sections, CDC consensus panels, committees within the ACTG and the NYS DOH AIDS Institute, and the Planning Committee of the NYCDOMH New York Hepatitis C Research Consortium. He is the Director, Infectious Diseases Core, in the NIDA-funded multi-institutional P30 Center for Drug Use and HIV Research (CDUHR) where his role is to facilitate multi-disciplinary interactions and research among biomedical and socio-behavioral scientists.
He is an active clinician, doing inpatient consultative infectious diseases and a full range of office infectious diseases.
Language
Position
Hospital Affiliations
- Mount Sinai Beth Israel
- Mount Sinai Morningside
- Mount Sinai Queens
- The Mount Sinai Hospital
- New York Eye and Ear Infirmary of Mount Sinai
- Mount Sinai West
Research Topics
Addiction, Biomedical Sciences, Epidemiology, Global Health, HIV/AIDS, Hepatitis C Virus, Infectious Disease
About Me
David C. Perlman, MD is Professor of Medicine and Associate Chief, Infectious Diseases at Mount Sinai Beth Israel. He is also Investigator in the Baron Edmund De Rothschild Chemical Dependency Institute at Mount Sinai Beth Israel, and a member of the Institute of Advanced Medicine.
He has over 20 years’ experience in HIV, HCV and related in substance using population and remains active as a clinician in these areas. He has served as principal investigator on multi-center trials within NIAID’s AIDS Clinical Trials group, and on R01 grants from NIDA. He has served on NIH study sections, CDC consensus panels, committees within the ACTG and the NYS DOH AIDS Institute, and the Planning Committee of the NYCDOMH New York Hepatitis C Research Consortium. He is the Director, Infectious Diseases Core, in the NIDA-funded multi-institutional P30 Center for Drug Use and HIV Research (CDUHR) where his role is to facilitate multi-disciplinary interactions and research among biomedical and socio-behavioral scientists.
He is an active clinician, doing inpatient consultative infectious diseases and a full range of office infectious diseases.
He has over 20 years’ experience in HIV, HCV and related in substance using population and remains active as a clinician in these areas. He has served as principal investigator on multi-center trials within NIAID’s AIDS Clinical Trials group, and on R01 grants from NIDA. He has served on NIH study sections, CDC consensus panels, committees within the ACTG and the NYS DOH AIDS Institute, and the Planning Committee of the NYCDOMH New York Hepatitis C Research Consortium. He is the Director, Infectious Diseases Core, in the NIDA-funded multi-institutional P30 Center for Drug Use and HIV Research (CDUHR) where his role is to facilitate multi-disciplinary interactions and research among biomedical and socio-behavioral scientists.
He is an active clinician, doing inpatient consultative infectious diseases and a full range of office infectious diseases.
Language
Position
Hospital Affiliations
- Mount Sinai Beth Israel
- Mount Sinai Morningside
- Mount Sinai Queens
- The Mount Sinai Hospital
- New York Eye and Ear Infirmary of Mount Sinai
- Mount Sinai West
Research Topics
Addiction, Biomedical Sciences, Epidemiology, Global Health, HIV/AIDS, Hepatitis C Virus, Infectious Disease
Clinical Focus
- Endocarditis
- HIV
- HIV Testing And Treatment Program
- HIV and AIDS
- Hepatitis
- Hepatitis A Vaccine
- Hepatitis B
- Hepatitis B Vaccine
- Hepatitis C
Show More
Video
Education
MD, Albert Einstein College of Medicine
BA, Dartmouth College
Residency, Internal Medicine
Memorial Sloan-Kettering Cancer Center
Fellowship, Infectious Disease
Albert Einstein College of Medicine-Yeshiva University
Certifications
American Board of Internal Medicine
Awards
2012
Best Doctors 2012, 2013, 2014, 2016, 2017 & 2018
NY Magazine
2005
President, Infectious Diseases Society of New York
2000
TB Committee, Infectious Disease Society of
Fellow, Infectious Disease Society of America
College on Problems of Drug Dependence
The Leo M. Davidoff Society - for excellence in teaching
Super Doctors 2014, 2015, 2017 & 2019
Research
His earlier work focused on studies of the epidemiology of tuberculosis among drug users, and on health care delivery models and behavioral and structural interventions to facilitate adherence to the TB care continuum. Recent work has focused on the delivery of other health care services (HIV, STI, HCV, HBV, others) to drug users in and out of drug abuse treatment, a qualitative and quantitative study of barriers and facilitators of HIV and HCV testing and care among ethnic minority drug users, and a “seek, test, treat and retain” intervention for high risk heterosexuals. A prominent line of inquiry has been improving adherence to multi-step heath care interventions and care continua in a variety of settings, including extensive work with drug using populations in and out of drug abuse treatment settings. His current work focuses on the HCV care continuum. He was PI of the NIDA funded “Bridges” project, an RCT of a combined case management-motivational interviewing intervention to promote adherence to off-site referral for HCV care from methadone maintenance treatment (published in AJPH and selected for the AHRQ New Innovations Exchange). He is actively involved in a number of ongoing projects.
Locations
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.
Patients with Cigna Medicare Advantage or Humana Medicare Advantage insurance: Please read this important message before booking to find out if out-of-network costs may apply to your next visit.
- Mount Sinai Union Square10 Union Square East, Suite 2H/J, New York, NY, 10003
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Selected Publications
- “New Normal:” Opportunities and Challenges Faced by Syringe Service Programs Following the Effects of the COVID-19 Pandemic. Elizabeth J. Austin, Elsa S. Briggs, Maria A. Corcorran, Jessica Chen, Nicky Cotta, Czarina N. Behrends, Stephanie M. Prohaska, Paul A. LaKosky, Shashi N. Kapadia, David C. Perlman, Bruce R. Schackman, Don C. Des Jarlais, Emily C. Williams, Sara N. Glick. Substance Use and Misuse
- Historical and theoretical roots of the big events framework. Samuel R. Friedman, Diana Rossi, David C. Perlman. International Journal of Drug Policy
- The Urgent Need to Implement Point-of-Care RNA Testing for Hepatitis C Virus to Support Elimination. Shashi N. Kapadia, Ashly E. Jordan, Benjamin J. Eckhardt, David C. Perlman. Clinical Infectious Diseases
Patient Experience Star Ratings and Comments
The Patient Experience Star Rating reflects our patients’ perception of how well their Mount Sinai provider communicated with them during an office visit. The Star Rating is based on patient responses to three questions on a patient experience survey, a standardized questionnaire sent to verified patients and distributed by a third party vendor, Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score.
Care Provider’s Explanation
Care Provider’s Concern
Likelihood to Recommend Care Provider
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Perlman has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Perlman has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.